Financial Data and Key Metrics Changes - The second quarter revenues were $231 million, with core revenue growth of 3.5% excluding foreign currency impacts, acquisitions, and discontinued product lines [27] - Adjusted EBITDA was $51 million, representing a margin of 22.2%, with a sequential improvement of 210 basis points [35] - Gross margin decreased to 49%, down 190 basis points from 50.9% in the same quarter a year ago [35] Business Line Data and Key Metrics Changes - In the food safety segment, revenues were $164 million, flat compared to the prior year, with core growth of nearly 4% led by biosecurity products [28] - The animal safety segment reported revenues of $67 million, with core revenue growth of 3.2% compared to the prior year [30] - Genomics business saw a mid-single-digit decline in core growth year-over-year, primarily due to weakness in the companion animal side [18] Market Data and Key Metrics Changes - Core revenue growth was led by Latin America with double-digit growth, while Europe saw high single-digit growth [32] - The U.S. and Canada region experienced flat core revenue compared to the prior year, impacted by shipping delays [34] Company Strategy and Development Direction - The company is focusing on restructuring its genomics business to enhance profitability and streamline operations [21] - There is an ongoing portfolio review to explore strategic alternatives for parts of the animal safety segment [22] - The company aims to leverage its broad product portfolio to address increasing consumer and regulatory focus on food safety [12][13] Management's Comments on Operating Environment and Future Outlook - Management noted gradual improvement in core revenue growth and free cash flow, despite challenges in the food safety market due to inflation and lower food production [7][8] - The company updated its full-year outlook, citing foreign exchange headwinds and lower genomics revenue as significant factors [24][40] - Management expressed confidence in the long-term prospects of the business despite current challenges, emphasizing the importance of food safety [50] Other Important Information - The company is in the process of ramping up production in its relocated sample collection facility, expecting to reach prior production levels by the end of Q3 [20] - A goodwill impairment charge was recorded due to the acquisition of the former 3M food safety division, reflecting integration complexities [37][43] Q&A Session Summary Question: Implications of lower revenue base on margins - Management acknowledged that while revenue may decrease, focusing on higher quality revenue can support desired margin profiles [56][60] Question: Trends in sample handling and customer retention - Management confirmed that losing product availability has led to customer shifts, but they are regaining market share as production ramps up [64][66] Question: Impact of food regulation changes on business - Management highlighted potential long-term benefits from increased regulatory focus on food safety, positioning the company as a trusted partner [69][72] Question: Magnitude of currency impacts and genomic attrition - Management indicated that foreign exchange and genomics revenue reductions were significant contributors to the guidance reduction [75][76] Question: Customer sentiment regarding sample handling - Management reported improving customer sentiment as supply issues are resolved, leading to regained customer trust [86] Question: Future of animal safety segment - Management expressed confidence in the animal safety segment's recovery, noting positive trends in distributor sales [90]

Group 1 - Neogen reported quarterly earnings of $0.11 per share, matching the Zacks Consensus Estimate, and the same as the previous year [1] - The company posted revenues of $231.26 million for the quarter ended November 2024, exceeding the Zacks Consensus Estimate by 2.16% and showing a slight increase from $229.63 million a year ago [2] - Neogen shares have increased approximately 7.7% since the beginning of the year, outperforming the S&P 500's gain of 0.6% [3] Group 2 - The earnings outlook for Neogen is uncertain, with current consensus EPS estimates at $0.15 for the coming quarter and $0.51 for the current fiscal year [7] - The estimate revisions trend for Neogen is currently unfavorable, resulting in a Zacks Rank 4 (Sell), indicating expected underperformance in the near future [6] - The Medical - Products industry, to which Neogen belongs, is ranked in the bottom 44% of over 250 Zacks industries, suggesting potential challenges for stock performance [8]

Exhibit 99.1 Neogen Announces Preliminary 1 Second-Quarter 2025 Results 1 Results presented in this release are preliminary and unaudited estimates based on information currently available to the Company. Such results could differ from the final amounts the Company reports in its Quarterly Report on Form 10-Q for the fiscal quarter ended November 30, 2024. The Company assumes no obligation, and does not intend, to update these estimates prior to filing its Form 10-Q. 2 Non-GAAP financial measures; see expla ...

Revenue of $231.3 million. Net loss of $456.3 million due to non-cash goodwill impairment; $(2.10) per diluted share. Adjusted Net Income2 of $24.4 million; $0.11 per diluted share. Adjusted EBITDA2 of $51.4 million. Updating full-year guidance.LANSING, Mich., Jan. 10, 2025 /PRNewswire/ -- Neogen Corporation (NASDAQ: NEOG) announced today the preliminary results of the second quarter ended November 30, 2024."The second quarter reflected steady progress, as we saw improvement across the business compared to ...

LANSING, Mich., Jan. 7, 2025 /PRNewswire/ -- Neogen® Corporation (NASDAQ: NEOG) announced today that the Company will participate in two upcoming investor conferences. The Company will participate in the CJS Securities 25th Annual Investor Conference, held virtually on January 14, 2025. John Adent, Neogen's President and CEO, will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California, on January 15, 2025, at 3:45 PM PT. To access the webcast and presentation materials for ...

In its upcoming report, Neogen (NEOG) is predicted by Wall Street analysts to post quarterly earnings of $0.11 per share, reflecting no change compared to the same period last year. Revenues are forecasted to be $226.37 million, representing a year-over-year decrease of 1.4%.The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.P ...

Neogen's (NEOG) vast international trade is being impacted by global macroeconomic issues. Also, a tough competitive landscape weighs on the stock. NEOG stock carries a Zacks Rank #4 (Sell) currently.Factors Pulling NEOG Stock DownNeogen’s international business continues to be affected due to currency movements. During the fiscal first quarter, the company faced a foreign currency headwind of 390 basis points. Further, the current macroeconomic environment has been affecting Neogen’s financial operations. ...

LANSING, Mich., Dec. 19, 2024 /PRNewswire/ -- Neogen® Corporation (NASDAQ: NEOG) will issue its second-quarter earnings release before the opening of the market on Thursday, January 9, 2025. Executives from the company will host a webcast and conference call later that morning, beginning at 8:00 a.m. Eastern time, to discuss the financial results.The conference call can be accessed by dialing (800) 836-8184 (U.S.) or +1 (646) 357-8785 (international) and requesting the Neogen Corporation Q2 FY25 Earnings Ca ...

Neogen Corporation (NEOG) , an innovative leader in food safety solutions, recently introduced the Neogen Petrifilm Bacillus cereus Count Plate. This solution offers food safety professionals a simple, reliable, and efficient testing method for Bacillus cereus. Petrifilm Bacillus cereus Count Plate is the latest addition to the company’s Petrifilm product line.NEOG’s Likely Stock Trend Following the NewsFollowing the announcement, shares of NEOG moved 2.36% north to $12.13 yesterday.  Neogen consistently de ...

LANSING, Mich., Dec. 17, 2024 /PRNewswire/ -- Neogen® Corporation (NASDAQ: NEOG), an innovative leader in food safety solutions, has introduced a new addition to its Petrifilm® product line, the Neogen Petrifilm Bacillus cereus Count Plate.This innovative new solution offers food safety professionals a simple, reliable, and efficient method for testing for Bacillus cereus, a persistent threat with potentially deadly consequences. The Petrifilm Bacillus cereus Count Plate provides comprehensive testing for t ...